The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Within the PD-(L)1 class, Keytruda is responsible for over 55% of the total global sales. Its current revenue total makes ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

Innovative drug development "the flavor of 2025" says Ali Pashazadeh, who discusses how the new administration will likely ...

First Immutep reported on positive data from the Phase I trial evaluating its eftilagimod alpha (efti) in combination with ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...